Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction and female sexual dysfunction .
Categories
- Andropause
- Anti-Aging Medicine
- Biotechnology
- Endocrinology
- Exercise And Fitness
- Gene therapy
- HCG Therapy
- Hormone Replacement Therapy
- Infertility
- Integrative Medicine
- Longevity
- Longevity Medicine
- Menopause Management
- Nutraceuticals
- Nutrition
- Preventative Medicine
- Regenerative Medicine
- Sexual Dysfunction
- Stem Cell Therapy
- Testosterone
- Weight Management
Archives